Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 5 Issue: 7, November

Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications

Volume:5   Issue: 7
Pp: 471-488
Pouya Pakneshan, Moshe Szyf and Shafaat A. Rabbani
DOI: 10.2174/156800905774574011
Published on: 01 March, 2012

Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer

Volume:5   Issue: 7
Pp: 489-503
Donna L. Livant
DOI: 10.2174/156800905774574002
Published on: 01 March, 2012

Cancer Therapy Through Control of Cell Migration

Volume:5   Issue: 7
Pp: 505-518
Eugene G. Levin
DOI: 10.2174/156800905774574048
Published on: 01 March, 2012

Inhibition of Angiogenesis by Cleaved High Molecular Weight Kininogen (HKa) and HKa Domain 5

Volume:5   Issue: 7
Pp: 519-528
Keith R. McCrae, Fernando Donate, Sergei Merkulov, Danyu Sun, Xiaoping Qi and David E. Shaw
DOI: 10.2174/156800905774574039
Published on: 01 March, 2012

Anti-Angiogenic and Anti-Tumor Properties of Proteasome Inhibitors

Volume:5   Issue: 7
Pp: 529-541
Kenyon G. Daniel, Deborah J. Kuhn, Aslamuzzaman Kazi and Q. P. Dou
DOI: 10.2174/156800905774574075
Published on: 01 March, 2012

Control of Copper Status for Cancer Therapy

Volume:5   Issue: 7
Pp: 543-549
Vicki L. Goodman, George J. Brewer and Sofia D. Merajver
DOI: 10.2174/156800905774574066
Published on: 01 March, 2012

Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose

Volume:5   Issue: 7
Pp: 551-559
Yuval Shaked, Guido Bocci, Raquel Munoz, Shan Man, John M.L. Ebos, Daniel J. Hicklin, Francesco Bertolini, Robert D'Amato and Robert S. Kerbel
DOI: 10.2174/156800905774574020
Published on: 01 March, 2012